State ordering guide
Sourcing Exosomes in Florida
Licensed Florida practices order Kimera exosome material from ExaVeyra as research-grade product, shipped cold-chain from Miami Beach with a Certificate of Analysis and lot traceability on every vial. Florida buyers need their own professional license and NPI; the wholesale distribution permit is the supplier’s obligation, not the purchaser’s.
Florida is ExaVeyra’s home state. Cold-chain orders reach Florida practices within one to three business days, and Miami-Dade, Broward, and Palm Beach sit on the shortest lane we run.
At a glance
| Question | Answer |
|---|---|
| Does ExaVeyra ship to Florida? | Yes. Cold-chain from Miami Beach, as we do to all 50 states |
| Cold-chain transit from Miami | 1 to 3 business days |
| State regenerative-medicine statute | SB 1768 (2025) |
| Does that statute reach exosomes? | No. Its definition is written around cells; exosomes are acellular and governed federally |
| Physician delegation required to hand off medical acts | Yes |
| Who holds the wholesale distribution permit | The supplier, not the purchasing practice |
| What ExaVeyra supplies here | Kimera exosome material and 503A compounded preparations |
| Last reviewed | 9 August 2026 |
Ordering from Florida
ExaVeyra ships to licensed practices in all 50 states, and Florida is our home market. Distribution-side licensing is handled by us, so your practice orders against its own professional license and NPI. What varies state to state is not whether product can reach you, but the indications it may be used for under federal law and how your state regulates who performs the procedure.
What your practice provides
- An active Florida professional license in good standing, verifiable through the Department of Health’s MQA license portal.
- A valid NPI, which ExaVeyra verifies at account setup.
- A signed research-use acknowledgment on file for exosome material.
- A Florida Annual Resale Certificate for Sales Tax (form DR-13) if the practice is purchasing for resale rather than for use in its own operations.
How the state permits wholesale distribution
Florida’s wholesale distribution permits are administered by DBPR rather than the Department of Health, and they attach to prescription drugs. Distribution of devices does not require a wholesale distributor permit. An out-of-state distributor selling prescription drugs into Florida applies on form DBPR-DDC-214 and pays a biennial fee.
Fla. Stat. ch. 499; Fla. Admin. Code r. 61N-2.012, 61N-2.016 · Florida Department of Business and Professional Regulation, Division of Drugs, Devices and Cosmetics
Florida regenerative-medicine law
Florida enacted SB 1768, codified at Fla. Stat. §§ 458.3245, 459.0127, effective 1 July 2025.
Physicians licensed under Fla. Stat. ch. 458 (MD) or ch. 459 (DO), acting within their scope of practice. The statute requires written informed consent signed by the patient before a non-FDA-approved stem cell therapy is performed, and violations are subject to Board of Medicine or Board of Osteopathic Medicine discipline.
- Orthopedic conditions
- Wound care
- Pain management
“a treatment involving the use of afterbirth placental perinatal stem cells, or human cells, tissues, or cellular or tissue-based products”
How this applies to exosomes
Florida’s stem cell law is frequently assumed to cover exosomes. It does not. SB 1768 defines its subject as afterbirth placental perinatal stem cells and human cells, tissues, or cellular or tissue-based products. Exosomes are acellular extracellular vesicles rather than cells or tissue, and the statute does not address them either to permit or to restrict. Exosome products remain governed by federal law, under which no exosome product has been approved by the FDA for administration to humans. ExaVeyra supplies Kimera material for topical aesthetic use in clinics and for research applications, with full COA and lot documentation.
Who can handle product in a Florida practice
Delegation in Florida runs through the Medical Practice Act. A physician may delegate a medical act only where it is within the delegate’s license, training, and competence, and the delegating physician retains responsibility. Practices generally maintain written protocols and signed delegation agreements documenting what has been delegated and to whom.
| Role | Scope under state law |
|---|---|
| MD / DO | Physicians licensed under chapter 458 (MD) or chapter 459 (DO) may perform medical acts within their scope of practice and are the source of any delegation to other staff. The delegating physician retains responsibility for a delegated act. |
| NP / APRN | Advanced practice registered nurses practice under chapter 464 within their certification and established protocol. Florida’s autonomous practice registration under section 464.0123 is limited to primary care practice and does not extend to dermatologic or aesthetic services, so aesthetic APRN practice continues under a physician protocol. |
| PA | Physician assistants practice under chapter 458 or 459 within the scope delegated by their supervising physician. |
| RN | Registered nurses practice under the Nurse Practice Act (chapter 464) and may perform delegated medical acts that fall within the scope of their license, training, and demonstrated competence. |
Good faith examination
Florida does not use the term “good faith examination”; the requirement is framed around establishing a patient-provider relationship and an appropriate prior examination, including a review of medical history and a diagnosis, before treatment. Florida Board of Medicine guidance places that examination with a physician, physician assistant, or advanced registered nurse practitioner. Telehealth may be used where it meets the standard of care and documentation requirements.
Ownership and clinic licensing
Florida does not restrict medical practice ownership as tightly as strict corporate-practice-of-medicine states, and non-physician ownership of aesthetic practices is common. The consequential question for most Florida practices is instead the Health Care Clinic Act: an entity providing health care services to the public and billing for them is presumptively a clinic requiring licensure from the Agency for Health Care Administration unless it qualifies for an exemption.
Cold chain into Florida
Shipments dispatch from our Miami Beach facility under validated temperature monitoring, and delivery into Florida is scheduled to avoid a weekend hold at the carrier hub.
| Metro | County | Notes |
|---|---|---|
| Miami | Miami-Dade | Highest concentration of aesthetic and regenerative practices in the state, and our home market. |
| Fort Lauderdale | Broward | Dense med spa and concierge corridor along the Broward coast. |
| West Palm Beach | Palm Beach | Concierge and longevity practices serving a year-round population. |
| Tampa | Hillsborough | Orthopedic, sports medicine, and aesthetic practices across the Bay area. |
| Orlando | Orange | Central Florida hub with a broad mix of dermatology and aesthetic practices. |
| Jacksonville | Duval | North Florida market with a strong surgical and recovery presence. |
- Florida orders of six or more cold-chain units ship free; see the volume program for current thresholds.
- Inspect the temperature indicator on arrival and contact us before use if the shipment reads outside range.
- Storage and handling conditions for each product are stated on its Certificate of Analysis.
Practice types we supply in Florida
Florida sourcing questions
- Does Florida’s stem cell law let my practice offer exosome treatments?
- No. Florida SB 1768 addresses stem cell therapy, which it defines as afterbirth placental perinatal stem cells and human cells, tissues, or cellular or tissue-based products, for orthopedic conditions, wound care, and pain management. Exosomes are acellular and fall outside that definition, so the statute neither permits nor restricts them. Exosome products are governed federally, and no exosome product is FDA-approved for administration to humans.
- Does my Florida clinic need a wholesale distributor permit to buy exosomes?
- No. Florida’s prescription drug wholesale distributor permit is held by the distributor selling into the state, not by the practice buying. Your practice orders against its own professional license and NPI. ExaVeyra handles distribution-side licensing.
- What does ExaVeyra verify before opening a Florida account?
- An active Florida professional license checked against the Department of Health MQA portal, a valid NPI, and a signed research-use acknowledgment for exosome material. Practices buying for resale also provide a Florida Annual Resale Certificate (form DR-13).
- How long does cold-chain shipping take within Florida?
- Overnight to Florida practices once prepared, with preparation taking one to two business days. Miami-Dade, Broward, and Palm Beach sit on the shortest lane we run, since our facility is in Miami Beach. All exosome shipments travel cold-chain with validated temperature monitoring, and deliveries are scheduled to avoid a weekend hold at the carrier hub.
- How should exosome material be handled on arrival?
- Check the temperature indicator included with the shipment before the vials go into storage, and move them to their storage condition promptly. If the indicator reads outside range, contact us before use rather than storing the shipment. Storage and handling conditions for each product are stated on its Certificate of Analysis.
- Who in a Florida practice can handle exosome material?
- Physicians licensed under chapter 458 or 459 may act within their scope and delegate to qualified staff. Physician assistants and advanced practice registered nurses work within their delegated or protocol scope, and registered nurses may perform delegated acts within their license, training, and competence. Note that Florida’s autonomous APRN registration is limited to primary care and does not extend to aesthetic services. Confirm your own protocols with Florida counsel.
- Is documentation available for each lot?
- Yes. A Certificate of Analysis is issued for every Kimera lot and provided on request, and every vial carries its lot number. COAs include particle characterization and sterility panel data, and are available for review before you order.
Material available to licensed Florida practices
Kimera Labs preparations distributed by ExaVeyra, characterised on the certificate of analysis supplied with every lot. Research-grade material for licensed practices; the practitioner determines clinical use.
- Luxir
1 Trillion Microvesicles · 5 Trillion Microvesicles
Available formats: 1.0 mL, 5.0 mL
- Luxir+
3 Trillion Microvesicles · 15 Trillion Microvesicles
Available formats: 1.0 mL, 5.0 mL
- Kiara
3 mg secretome · 15 mg secretome
Available formats: 1.0 mL, 5.0 mL
- Vive
2 Trillion Microvesicles
Available formats: 5.0 mL
Sources
Last reviewed 9 August 2026 by ExaVeyra Sciences editorial team. Every claim above links to a primary source.
- Florida SB 1768 (2025) enrolled bill text (accessed 8 August 2026)
- Fla. Stat. sec. 458.3245, stem cell therapy (accessed 8 August 2026)
- DBPR Division of Drugs, Devices and Cosmetics, permit FAQs (accessed 8 August 2026)
- Fla. Admin. Code r. 61N-2.012, out-of-state prescription drug wholesale distributor permit (accessed 8 August 2026)
- Florida Department of Revenue, Annual Resale Certificate for Sales Tax (accessed 8 August 2026)
- FDA Public Safety Notification on Exosome Products (accessed 8 August 2026)
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. There are no FDA-approved exosome products. Biomolecular signaling vesicle products distributed by ExaVeyra Sciences are supplied for topical aesthetic treatments in clinics and for medical, molecular biology, and biochemistry research applications, and are not tissue products as defined by FDA guidelines.
Reference only. Not legal or medical advice.
The content of these guides is provided for general informational purposes only. It does not constitute legal, medical, or regulatory advice, and does not establish that any particular product or practice is compliant. Regulatory requirements vary by state and depend on the circumstances of each practice. Each practitioner should consult their own legal counsel and the applicable state licensing boards before acting on anything stated here.
Read the full disclaimer
ExaVeyra Sciences publishes these guides as a reference for licensed practitioners. They summarize publicly available federal and state requirements as those requirements read on the review date shown above. The content is provided for general informational purposes only and does not constitute legal, medical, or regulatory advice, and it does not establish that any particular product or practice is compliant.
No attorney-client relationship, and no professional or clinical relationship of any kind, is created by accessing these materials. ExaVeyra Sciences is a supplier of research-use materials. It is not a law firm, it is not a regulatory consultant, and it takes no part in any diagnosis, treatment decision, or plan of care. Each practitioner is responsible for retaining their own legal counsel and for determining, with that counsel and the applicable state licensing boards, how the requirements described here apply to the services, staffing, and structure of their own practice.
Statutes, regulations, board rules, and agency positions are subject to amendment, supersession, and reinterpretation. ExaVeyra Sciences makes no representation or warranty as to the accuracy, completeness, timeliness, or applicability of this content to any particular practice. Citations and links to third-party sources are provided for convenience only and do not constitute an endorsement of their content.
The practitioner and the practice are solely responsible for compliance with all applicable licensing, scope of practice, supervision, ownership, facility, recordkeeping, and tax requirements, and for all clinical decisions, including the suitability of any material for a given patient. To the fullest extent permitted by law, ExaVeyra Sciences disclaims all liability for any action taken or not taken in reliance on this content.